Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Jun 12 03:31PM ET
0.1518
Dollar change
-0.0125
Percentage change
-7.61
%
Index- P/E- EPS (ttm)-6.95 Insider Own4.98% Shs Outstand14.18M Perf Week-4.89%
Market Cap2.15M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float13.48M Perf Month-15.05%
Income-18.10M PEG- EPS next Q- Inst Own1.44% Short Float15.78% Perf Quarter-56.25%
Sales0.00M P/S- EPS this Y- Inst Trans-44.08% Short Ratio0.54 Perf Half Y-89.23%
Book/sh1.16 P/B0.13 EPS next Y- ROA-88.26% Short Interest2.13M Perf Year-92.63%
Cash/sh0.41 P/C0.37 EPS next 5Y- ROE-121.95% 52W Range0.15 - 2.24 Perf YTD-86.80%
Dividend Est.- P/FCF- EPS past 5Y50.65% ROIC-130.74% 52W High-93.22% Beta2.07
Dividend TTM- Quick Ratio1.37 Sales past 5Y- Gross Margin- 52W Low0.60% ATR (14)0.03
Dividend Ex-Date- Current Ratio1.37 EPS Y/Y TTM27.04% Oper. Margin- RSI (14)37.68 Volatility5.46% 7.99%
Employees2 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price32.00
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q92.95% Payout- Rel Volume1.61 Prev Close0.16
Sales Surprise-14.63% EPS Surprise-79.41% Sales Q/Q- Earnings- Avg Volume3.91M Price0.15
SMA20-11.19% SMA50-27.76% SMA200-83.14% Trades Volume5,858,323 Change-7.61%
May-08-25 09:20AM
Apr-22-25 09:15AM
Apr-16-25 09:15AM
Mar-18-25 09:25AM
Mar-17-25 09:15AM
09:00AM Loading…
Mar-05-25 09:00AM
Feb-25-25 09:20AM
Jan-29-25 09:15AM
Jan-15-25 09:15AM
Dec-19-24 09:15AM
Dec-09-24 09:00AM
Oct-02-24 09:10AM
Aug-21-24 09:00AM
Jul-24-24 09:05AM
Jul-22-24 09:00AM
07:52AM Loading…
Jul-15-24 07:52AM
Jun-17-24 09:00AM
May-21-24 09:00AM
09:00AM
May-17-24 03:52PM
Apr-09-24 08:21AM
Mar-05-24 09:15AM
Feb-13-24 11:45AM
Dec-29-23 12:45PM
Dec-06-23 09:15AM
Oct-19-23 09:00AM
Oct-04-23 07:30AM
Aug-14-23 08:30AM
Aug-02-23 08:30AM
Jul-31-23 09:00AM
08:30AM Loading…
Apr-12-23 08:30AM
Mar-20-23 08:55AM
Mar-08-23 08:30AM
Mar-02-23 08:30AM
Feb-28-23 08:30AM
Feb-21-23 08:45AM
Dec-06-22 09:40AM
Nov-17-22 08:00AM
Nov-14-22 08:00AM
Sep-20-22 08:00AM
Aug-30-22 08:30AM
Aug-03-22 09:45AM
Jul-29-22 09:19AM
Jul-26-22 07:30AM
Jul-12-22 09:30AM
Jun-21-22 10:30AM
Apr-05-22 09:15AM
Mar-24-22 09:26AM
Feb-23-22 09:15AM
Feb-20-22 08:37AM
Feb-08-22 09:15AM
Feb-07-22 08:38PM
Jan-05-22 09:15AM
Dec-29-21 09:15AM
Dec-16-21 10:50AM
Dec-01-21 10:05AM
Nov-23-21 09:25AM
Nov-18-21 09:15AM
Nov-16-21 09:25AM
Nov-15-21 09:45AM
Oct-26-21 10:30AM
Oct-19-21 10:30AM
Oct-05-21 10:00AM
Sep-22-21 11:00AM
Sep-13-21 10:00AM
Sep-09-21 10:15AM
Aug-24-21 10:17AM
Aug-23-21 08:47AM
Aug-10-21 02:30PM
10:30AM
Aug-05-21 10:30AM
Jul-27-21 09:15AM
Jul-07-21 09:00AM
Jun-07-21 10:02AM
May-17-21 09:00AM
May-12-21 09:00AM
May-10-21 09:00AM
Apr-28-21 10:13AM
Apr-22-21 09:20AM
TNF Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of drug products to extend healthy lifespan. It focuses on developing two novel therapeutic platforms, MyMD-1 and SUPERA-CBD, which aim to treat the causes of disease rather than just addressing the symptoms. MyMD-1 is a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cytokines. SUPERA-CBD is a synthetic derivative of cannabidiol being developed to treat conditions such as epilepsy, chronic pain, depression, as well as neuroinflammatory and neurodegenerative diseases. The company was founded in 1989 and is headquartered in New York, NY.